Home » Newsletters » BioWorld Science

BioWorld Science

June 3, 2002

View Archived Issues

Abreva approved for OTC sale in Canada, Korea

Photofrin sNDA filed, orphan drug status granted, in high-grade dysplasia in Barrett's esophagus

Sankyo and Ube present antibacterial quinolizinones

New prenyltransferase inhibitors in early development at Merck

Fujisawa patents series for use in urinary incontinence

Novel calcilytic compounds and their use described in GSK patent

Aventis Pharma presents novel NHE3 inhibitors

VLA-4 antagonists with potential in asthma and inflammation

Antitumor xanthone compounds obtained from Streptomyces

Heat shock protein coinducer BRX-220 effective in rat model of acute pancreatitis

Effects of new SERM on bone, cholesterol and uterus compared to EE2 and levormeloxifene

Endogenous neuroprotective factor identified by Japanese group

Final analysis of phase III data for Zamyl in AML

Survival benefit for long-term atrasentan in HRPCa

Delay in PSA and clinical progression of prostate cancer achieved using Prostvac

KRX-211 has potential in septic shock

Neurontin receives FDA approval for postherpetic neuralgia

HIV immune responses induced by Remune plus CpG adjuvant in monkeys

Phase I study of aplidine as a three-hour infusion in solid tumor patients

Phase I/II enrollment completed for HuMax-IL-15 in rheumatoid arthritis

Endocyte licenses Galenica's GP-0100 for vitamin-based cancer treatments

Vion reprioritizes development program

Interim data announced from Neotrofin pilot study in Parkinson's disease

CPMP recommends approval of Visudyne in occult subfoveal CNV secondary to AMD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...